முடிவு முடிவுகள் ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from முடிவு முடிவுகள் ப்ரோக்ர்யாம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In முடிவு முடிவுகள் ப்ரோக்ர்யாம் Today - Breaking & Trending Today

Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction


Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction
News provided by
Share this article
Share this article
SUZHOU, China, July 28, 2021 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to TST001, its anti-Claudin18.2 monoclonal antibody currently in Phase I clinical trial, for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ). According to preclinical and clinical data, TST001 displayed potent anti-tumor activities in tumor model of gastric cancer or patient of gastric cancer expressing Claudin18.2. ....

United States , Los Angeles , Michael Shi , Clinical Development Centers , Transcenta Holding , Drug Administration , Product Development Center , Translational Research Center , Prnewswire Transcenta Holding Limited , National Cancer Institute Surveillance , End Results Program , Business Development , Transcenta Immune Tolerance Breaking Technology , Holding Limited , Orphan Drug Designation , National Cancer Institute , Drug Designation , Immune Tolerance Breaking Technology , Manufacturing Facility , External Partnering Center , ஒன்றுபட்டது மாநிலங்களில் , லாஸ் ஏஞ்சல்ஸ் , மைக்கேல் ஷி , மருத்துவ வளர்ச்சி மையங்கள் , ப்ராடக்ட் வளர்ச்சி மையம் , மொழிபெயர்ப்பு ஆராய்ச்சி மையம் ,

Cancer detection biotech BARD1 raising $10 million


Cancer detection biotech BARD1 raising $10 million
Share
Bell Potter is hitting the streets for early cancer diagnostics company BARD1 Life Sciences this week, running a $12 million capital raise for the business.
The capital raise takes the form of a $10 million placement and a $2 million share purchase plan to eligible retail investors.
The business has reserved the rights to increase or reduce the the share purchase plan.
The offer comes at a 13.9 per cent discount to BARD1’s last close price at $1.55 per share.
The business is developing early detection tests for breast and ovarian cancers, which have shown to have sensitivity of more than 95 per cent and 100 per cent specificity. ....

End Results Program , End Results , முடிவு முடிவுகள் ப்ரோக்ர்யாம் , முடிவு முடிவுகள் ,

ALUNBRIG® (brigatinib) Approved for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase